TY - JOUR
T1 - Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk
AU - Kim, Iris Y.
AU - O'Reilly, Éilis J.
AU - Hughes, Katherine C.
AU - Gao, Xiang
AU - Schwarzschild, Michael A.
AU - McCullough, Marjorie L.
AU - Hannan, Marian T.
AU - Betensky, Rebecca A.
AU - Ascherio, Alberto
N1 - Funding Information:
*Corresponding author: Iris Y. Kim, Department of Epidemiology, Relevant conflicts of interests/financial disclosures: Nothing to report. Harvard T. H. Chan School of Public Health, 677 Huntington Ave, Boston, MA 02115; [email protected] Funding agencies: This study was supported by National Institutes of Health Grants UM1 CA186107 and UM1 CA167552 and by Department of Defense Grant W81XWH-14-0131.
Funding Information:
A.A. receives research funding from the National Institutes of Health, the Department of Defense, the National Multiple Sclerosis Society, and the ALS Association. X.G. has served on the committee of the Parkinson Study Group and received funding from the National Institutes of Health/National Institute of Neurological Disorders and Stroke. All other authors have nothing to report.
Publisher Copyright:
© 2018 International Parkinson and Movement Disorder Society
PY - 2018/3
Y1 - 2018/3
N2 - Background: Caffeine intake has been inversely associated with Parkinson's disease (PD) risk. This relationship may be modified by polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2), but the results of previous studies have been inconsistent. Method: We examined the interaction of caffeine intake with GRIN2A-rs4998386 and CYP1A2-rs762551 polymorphisms in influencing PD risk among 829 incident cases of PD and 2,754 matched controls selected among participants in the following 3 large prospective ongoing cohorts: the Nurses' Health Study, the Health Professionals' Follow-up Study, and the Cancer Prevention Study II Nutrition Cohort. Matching factors included cohort, birth year, source of DNA, date of DNA collection, and race. Relative risks and 95% confidence intervals were estimated using conditional logistic models. Interactions were tested both on the multiplicative scale and on the additive scale. Results: Overall, caffeine intake was associated with a lower PD risk (adjusted relative risk for highest versus lowest tertile = 0.70; 95% confidence interval, 0.57-0.86; p <.001). In analyses stratified by the GRIN2A-rs4998386 genotype, the multivariable-adjusted relative risk of PD comparing the highest to the lowest tertile of caffeine was 0.69 (95% confidence interval, 0.55-0.88; p <.01) among individuals homozygous for the C allele, and 0.85 (95% confidence interval, 0.55-1.32; p =.47; p RERI =.43) among carriers for the T allele. Interactions between caffeine and GRIN2A were not significant in either the multiplicative or additive scales. We also did not observe significant interactions for CYP1A2-rs762551 and incident PD risk. Conclusion: Our findings do not support the hypothesis of an interaction between the GRIN2A-rs4998386 or CYP1A2-rs762551 polymorphism and caffeine intake in determining PD risk.
AB - Background: Caffeine intake has been inversely associated with Parkinson's disease (PD) risk. This relationship may be modified by polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2), but the results of previous studies have been inconsistent. Method: We examined the interaction of caffeine intake with GRIN2A-rs4998386 and CYP1A2-rs762551 polymorphisms in influencing PD risk among 829 incident cases of PD and 2,754 matched controls selected among participants in the following 3 large prospective ongoing cohorts: the Nurses' Health Study, the Health Professionals' Follow-up Study, and the Cancer Prevention Study II Nutrition Cohort. Matching factors included cohort, birth year, source of DNA, date of DNA collection, and race. Relative risks and 95% confidence intervals were estimated using conditional logistic models. Interactions were tested both on the multiplicative scale and on the additive scale. Results: Overall, caffeine intake was associated with a lower PD risk (adjusted relative risk for highest versus lowest tertile = 0.70; 95% confidence interval, 0.57-0.86; p <.001). In analyses stratified by the GRIN2A-rs4998386 genotype, the multivariable-adjusted relative risk of PD comparing the highest to the lowest tertile of caffeine was 0.69 (95% confidence interval, 0.55-0.88; p <.01) among individuals homozygous for the C allele, and 0.85 (95% confidence interval, 0.55-1.32; p =.47; p RERI =.43) among carriers for the T allele. Interactions between caffeine and GRIN2A were not significant in either the multiplicative or additive scales. We also did not observe significant interactions for CYP1A2-rs762551 and incident PD risk. Conclusion: Our findings do not support the hypothesis of an interaction between the GRIN2A-rs4998386 or CYP1A2-rs762551 polymorphism and caffeine intake in determining PD risk.
KW - CYP1A2
KW - GRIN2A
KW - Parkinson's disease
KW - caffeine
KW - interaction
UR - http://www.scopus.com/inward/record.url?scp=85040345843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040345843&partnerID=8YFLogxK
U2 - 10.1002/mds.27279
DO - 10.1002/mds.27279
M3 - Article
C2 - 29318639
AN - SCOPUS:85040345843
SN - 0885-3185
VL - 33
SP - 414
EP - 420
JO - Movement Disorders
JF - Movement Disorders
IS - 3
ER -